Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Context Therapeutics (CNTX)
NASDAQ:CNTX
Holding CNTX?
Track your performance easily
CNTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.77 - $2.75
Previous Close$1.96
Volume48.50K
Average Volume (3M)209.07K
Market Cap
$147.00M
Enterprise Value$45.50M
Total Cash (Recent Filing)$101.50M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Nov 07, 2024EPS Estimate
-$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding74,998,312
10 Day Avg. Volume84,877
30 Day Avg. Volume209,071
Standard Deviation0.34
R-Squared0.12
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.45
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-11.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.29
Forecast
1Y Price Target
$6.83Price Target Upside206.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Context Therapeutics News
PremiumCompany Announcements
Context Therapeutics Bolsters Board with Industry Veterans
PremiumCompany Announcements
Context Therapeutics Acquires CT-95 for Cancer Trial Launch
Bulls Say, Bears Say
Bulls Say
Investor ConfidenceContext announced a $100M private placement financing with key healthcare investor groups, a sign of strong investor confidence.
Regulatory ProgressCTIM-76's IND application has been cleared by the FDA, which allows for the start of its Phase 1 trial and demonstrates regulatory progress.
Valuation PotentialAnalyst views suggest a valuation gap between Context and its peers, implying potential undervaluation of Context's stock.
Bears Say
ClinicalRisks associated with CTIM-76 include clinical, regulatory, commercial, financing, and intellectual property challenges.
Safety ConcernsHistorically, TCEs have faced challenges in solid tumors due to toxicity concerns, particularly cytokine release syndrome (CRS).
Treatment ChallengesHistorically, TCEs have faced challenges in treating solid tumors, particularly due to toxicity issues like cytokine release syndrome (CRS).
---
Ownership Overview
1.57%
Insiders
6.17% Mutual Funds
73.14% Other Institutional Investors
19.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CNTX FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.77 and its highest was $2.75 in the past 12 months.
What is Context Therapeutics’s market cap?
Currently, no data Available
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Aug 07, 2024. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.067 by $0.027.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -$0.05.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 74,998,314 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.067. Following the earnings report the stock price went up 2.564%.
Which hedge fund is a major shareholder of Context Therapeutics?
Among the largest hedge funds holding Context Therapeutics’s share is Driehaus Capital Management LLC. It holds Context Therapeutics’s shares valued at 5M.
---
Context Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.83 (206.28% Upside)
$6.83 (206.28% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.8%
Last 30 Days ▲ 16.3%
Last 30 Days ▲ 16.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.18%
12-Months-Change
Fundamentals
Return on Equity
-29.68%
Trailing 12-Months
Asset Growth
269.96%
Trailing 12-Months
Company Description
Context Therapeutics
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.
---
CNTX Stock 12 Month Forecast
Average Price Target
$6.83
▲(206.28% Upside)
Technical Analysis
Best Analysts Covering CNTX
1 Year
1 Year Success Rate
3/15 ratings generated profit
1 Year Average Return
-24.76%
reiterated a buy rating 5 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -24.76% per trade.
---